A – COMPOSITION
The President submits the main points of the general policy of the group and the considered strategic operations to the executive committee for their approval.
The members of the executive committee are:
President: Olivier LAUREAU
Executive Vice-Presidents: Claude BERTRAND, Béatrice BIHR, Nicolas BOUTS, Pascal BRIERE, Virginie DOMINGUEZ, Philippe GONNARD, Siham IMANI, Pascal LEMAIRE, Frédéric SESINI, Pierre VENESQUE.
The health crisis has further bolstered our efforts to drive therapeutic progress.
First and foremost, my thoughts go to the people who have contracted Covid-19 and their families. But we also can’t forget patients with other health issues, who have been affected indirectly but no less seriously, having to wait to be screened and treated.
Accelerating therapeutic innovation
Béatrice Bihr joined the Executive Committee as the Executive Vice President – Secretary General as of April 1, 2021.
Generic medicines, an opportunity for health care systems
Virginie Dominguez joined the Executive Committee as the Executive Vice President Digital, Data and Information Systems as of October 1, 2021.
Acting for and with patients
Ambitious strategic objectives for 2025
Results in line with our expectations
The results from 2019-2020 are solid and in line with our objectives, with revenue of €4.7 billion—up 1.6% at real exchange rates on the previous year.
A solid geographic footprint, building proximity with patients
Preparing production facilities of tomorrow
The other members of the foundation board are:
B – TERMS OF OFFICE
The term of office for members of the foundation board is 10 years.
The term of office for the President and Vice-Presidents is 5 years.
When their term of office ends: